Sequentially releasing self-healing hydrogel fabricated with TGFβ3-microspheres and bFGF to facilitate rat alveolar bone defect repair

IF 11.9 1区 医学 Q1 PHARMACOLOGY & PHARMACY
Fenglin Yu , Dezhi Geng , Zhanpeng Kuang , Shiyi Huang , Yating Cheng , Yini Chen , Fang Leng , Yu Bei , Yueping Zhao , Qingxia Tang , Yadong Huang , Qi Xiang
{"title":"Sequentially releasing self-healing hydrogel fabricated with TGFβ3-microspheres and bFGF to facilitate rat alveolar bone defect repair","authors":"Fenglin Yu ,&nbsp;Dezhi Geng ,&nbsp;Zhanpeng Kuang ,&nbsp;Shiyi Huang ,&nbsp;Yating Cheng ,&nbsp;Yini Chen ,&nbsp;Fang Leng ,&nbsp;Yu Bei ,&nbsp;Yueping Zhao ,&nbsp;Qingxia Tang ,&nbsp;Yadong Huang ,&nbsp;Qi Xiang","doi":"10.1016/j.ajps.2022.03.003","DOIUrl":null,"url":null,"abstract":"<div><p>Resorption and loss of alveolar bone leads to oral dysfunction and loss of natural or implant teeth. Biomimetic delivery of growth factors based on stem cell recruitment and osteogenic differentiation, as the key steps in natural alveolar bone regenerative process, has been an area of intense research in recent years. A mesoporous self-healing hydrogel (DFH) with basic fibroblast growth factor (bFGF) entrapment and transforming growth factor β3 (TGFβ3) - loaded chitosan microspheres (CMs) was developed. The formulation was optimized by multiple tests of self-healing, in-bottle inversion, SEM, rheological, swelling rate and <em>in vitro</em> degradation. <em>In vitro</em> tubule formation assays, cell migration assays, and osteogenic differentiation assays confirmed the ability of DFH to promote blood vessels, recruit stem cells, and promote osteogenic differentiation. The optimum DFH formula is 0.05 ml 4Arm-PEG-DF (20%) added to 1 ml CsGlu (2%) containing bFGF (80 ng) and TGFβ3-microspheres (5 mg). The results of <em>in vitro</em> release studied by Elisa kit, indicated an 95% release of bFGF in 7 d and long-term sustained release of TGFβ3. For alveolar defects rat models, the expression levels of CD29 and CD45, the bone volume fraction, trabecular number, and trabecular thickness of new bone monitored by Micro-CT in DFH treatment groups were significantly higher than others (*<em>P</em> &lt; 0.05, <em>vs</em> Model). HE and Masson staining show the same results. In conclusion, DFH is a design of bionic alveolar remodelling microenvironment, that is in early time microvessels formed by bFGF provide nutritious to recruited endogenous stem cells, then TGFβ3 slowly released speed up the process of new bones formation to common facilitate rat alveolar defect repair. The DFH with higher regenerative efficiency dovetails nicely with great demand due to the requirement of complicated biological processes.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"17 3","pages":"Pages 425-434"},"PeriodicalIF":11.9000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/f7/main.PMC9237629.pdf","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S181808762200040X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 9

Abstract

Resorption and loss of alveolar bone leads to oral dysfunction and loss of natural or implant teeth. Biomimetic delivery of growth factors based on stem cell recruitment and osteogenic differentiation, as the key steps in natural alveolar bone regenerative process, has been an area of intense research in recent years. A mesoporous self-healing hydrogel (DFH) with basic fibroblast growth factor (bFGF) entrapment and transforming growth factor β3 (TGFβ3) - loaded chitosan microspheres (CMs) was developed. The formulation was optimized by multiple tests of self-healing, in-bottle inversion, SEM, rheological, swelling rate and in vitro degradation. In vitro tubule formation assays, cell migration assays, and osteogenic differentiation assays confirmed the ability of DFH to promote blood vessels, recruit stem cells, and promote osteogenic differentiation. The optimum DFH formula is 0.05 ml 4Arm-PEG-DF (20%) added to 1 ml CsGlu (2%) containing bFGF (80 ng) and TGFβ3-microspheres (5 mg). The results of in vitro release studied by Elisa kit, indicated an 95% release of bFGF in 7 d and long-term sustained release of TGFβ3. For alveolar defects rat models, the expression levels of CD29 and CD45, the bone volume fraction, trabecular number, and trabecular thickness of new bone monitored by Micro-CT in DFH treatment groups were significantly higher than others (*P < 0.05, vs Model). HE and Masson staining show the same results. In conclusion, DFH is a design of bionic alveolar remodelling microenvironment, that is in early time microvessels formed by bFGF provide nutritious to recruited endogenous stem cells, then TGFβ3 slowly released speed up the process of new bones formation to common facilitate rat alveolar defect repair. The DFH with higher regenerative efficiency dovetails nicely with great demand due to the requirement of complicated biological processes.

Abstract Image

相继释放tgf - β3微球与bFGF制备的自愈水凝胶促进大鼠牙槽骨缺损修复
牙槽骨的吸收和丢失导致口腔功能障碍和自然牙或种植牙的丢失。基于干细胞募集和成骨分化的生长因子仿生递送作为自然牙槽骨再生过程的关键步骤,近年来已成为研究热点。制备了包埋碱性成纤维细胞生长因子(bFGF)和负载转化生长因子β3 (TGFβ3)壳聚糖微球(CMs)的介孔自愈水凝胶(DFH)。通过自愈、瓶内翻转、扫描电镜、流变学、溶胀率、体外降解等多项实验对其进行优化。体外小管形成实验、细胞迁移实验和成骨分化实验证实了DFH促进血管、募集干细胞和促进成骨分化的能力。最佳DFH配方为0.05 ml 4Arm-PEG-DF(20%)加入1 ml含bFGF(80 ng)和tgf - β3微球(5 mg)的CsGlu(2%)。酶联免疫吸附试验(Elisa kit)结果显示,bFGF在7 d内释放95%,tgf - β3长期缓释。对于牙槽缺损大鼠模型,DFH治疗组CD29、CD45表达水平、骨体积分数、骨小梁数、新生骨小梁厚度均显著高于其他各组(*P <0.05, vs模型)。HE染色与Masson染色结果相同。综上所述,DFH是一种仿生肺泡重塑微环境的设计,即在早期由bFGF形成的微血管为募集的内源性干细胞提供营养,然后缓慢释放的TGFβ3加速新骨形成的过程,共同促进大鼠肺泡缺损的修复。再生效率高的DFH很好地满足了复杂生物过程的巨大需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Asian Journal of Pharmaceutical Sciences
Asian Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
18.30
自引率
2.90%
发文量
11
审稿时长
14 days
期刊介绍: The Asian Journal of Pharmaceutical Sciences (AJPS) serves as the official journal of the Asian Federation for Pharmaceutical Sciences (AFPS). Recognized by the Science Citation Index Expanded (SCIE), AJPS offers a platform for the reporting of advancements, production methodologies, technologies, initiatives, and the practical application of scientific knowledge in the field of pharmaceutics. The journal covers a wide range of topics including but not limited to controlled drug release systems, drug targeting, physical pharmacy, pharmacodynamics, pharmacokinetics, pharmacogenomics, biopharmaceutics, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, pharmaceutical engineering, and material sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信